医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Zelis® Earns 2024 Great Place to Work® Certification in India

2024年07月09日 AM11:30
このエントリーをはてなブックマークに追加


 

HYDERABAD, India

Zelis, a leading provider of healthcare technology solutions, achieves Great Place to Work certification in India for the first time. The honor was determined based on local associates’ survey responses related to their experience at Zelis, the workplace culture, and their perception of Company leadership.

“It is an exciting time to be at Zelis and to be part of our growing team in India,” says Venu Kandimalla, SVP and General Manager of Zelis India. “Over the past year, we’ve successfully expanded our team and local operations. To be recognized as a regional workplace leader is a testament to the commitment of our associates and the special environment they have created in India.”

For Zelis India, the Great Place to Work certification comes just one year after the founding of the local office in Hyderabad, India. Zelis stood out for its ability to deliver exceptional development, learning, wellness, recognition, and corporate giving programs. The Company’s continued commitment to diversity, equity, inclusion, and belonging also separates it from others in the healthcare market. The recognition comes after Zelis celebrated its Great Place to Work certification in the United States for a second consecutive year.

Learn more about the award-winning Zelis culture and explore our current career opportunities.

About Zelis

Zelis is modernizing the healthcare financial experience by providing a connected platform that bridges the gaps and aligns interests across payers, providers, and healthcare consumers. This platform serves more than 750 payers, including the top 5 national health plans, BCBS insurers, regional health plans, TPAs and self-insured employers, and millions of healthcare providers and consumers. Zelis sees across the system to identify, optimize, and solve problems holistically with technology built by healthcare experts – driving real, measurable results for clients. Learn more at Zelis.com and follow us on LinkedIn to get the latest news.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240708680071/en/

CONTACT

Jon Gregalis

press [at] zelis.com

同じカテゴリーの記事 

  • Celltrion公布皮下注射英夫利西单抗(CT-P13 SC)的两年事后分析结果,强调剂量递增是控制炎症性肠病继发性失应答的可选方案
  • メディデータ、初期および後期臨床試験をサポートするRave Liteを発表
  • Medidata宣布推出Rave Lite以支持早期和后期临床试验的增长
  • サウジアラビア開発基金、セルビアとの初の提携で 3件の開発プロジェクトに2億500万ドルの拠出を発表
  • 沙特发展基金宣布首次进入塞尔维亚 ,资助三个发展项目,总额达2.05亿美元